目前医药板块与联合证券股票池的整体估值比较已不具有相对优势,对于医药行业整体给予中性的投资评级。投资机会一是来自于大盘好转带动整体估值水平上涨时,跟随大盘走势的行情;二是由于目前低市盈率个股由于对公司基本面认识深入而导致较低的估值水平恢复正常。 At present, the overall valuation of the pharmaceutical sector and the United Securities stock pool does not have a comparative advantage. For the pharmaceutical industry as a whole to give a neutral investment rating. Firstly, the investment opportunities come from the market that followed the broader market trend as the overall valuation improved, leading to higher market valuations. The second reason is that due to the deep understanding of the fundamentals of the company, the lower valuations have returned to normal.